In the track of medical devices, we will, with MEDA Co., Ltd. and NewScen Coast Bio Pharmaceutical Co., Ltd. as the core enterprises, strive to improve the independent R&D capabilities and product technology level and build an advantageous high-end product platform.

Taking Jinyao Pacific Pharmaceutical Co., Ltd. as the leader, we will cooperate with Zhongxin Pharmaceutical Plant to create a “variety + network + channel” model, apply international advanced warehousing management system and modern information technology to create an efficient drug circulation platform, and realize the “seamless connection” between the logistics industry and drug manufacturers, suppliers, downstream customers and related units.

With Tianjin Yumeijing Group Co., Ltd. and Tianjin Puguang Medical Materials Manufacturing Co., Ltd. as the core enterprises, we will professionally develop various special products to meet the health needs of consumers and protect the health of you and your family by relying on the Group Company’s advantages in R&D, production and quality inspection of pharmaceuticals.

With Jinyao Biotechnology (Tianjin) Co., Ltd. as the core enterprise, we will build a platform for the R&D of innovative drugs, and undertake the Group Company’s strategic tasks of R&D, introduction and incubation of innovative drugs.

Taking Jinyao Asset Management Co., Ltd. as the main body, we will build a group asset and investment management platform to lay a good foundation for future capital operation.

With Tianjin Pharmaceutical Design Institute Co., Ltd. and Tianjin Pharmaceutical Group Finance Co., Ltd. as the core enterprises, we will be engaged in medical engineering design, group finance and fund management to serve the high-quality development of the Group Company.